Auditory and Vestibular Function Evaluation in Patients With Solid Tumors Treated With Oxaliplatin-Containing Chemotherapy
- Define the prevalence of audiometrically detectable hearing loss in patients with solid
tumors treated with oxaliplatin.
- Describe the association of chemotherapy-induced peripheral neuropathy (CIPN) and
audiometrically detectable hearing loss in these patients.
- Describe the association of CIPN and patient self-reported scales including, Peripheral
Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap
OUTLINE: This is an exploratory study.
Patients will complete three self-reported questionnaires including the Peripheral
Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap Inventory.
Patients will also be asked a series of questions regarding symptoms or complaints about
hearing changes, tinnitus, and dizziness that they may have experienced prior to, during,
and after completion of chemotherapy. Patients will also undergo a hearing test.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
Observational Model: Cohort, Time Perspective: Prospective
Hearing loss as measured by Hearing Loss Inventory, Dizziness Handicap Inventory, and audiogram every 2 months during treatment, and then 2-4 weeks and 6 months after completion of study treatment
every 2 months during treatment, and then 2-4 weeks and 6 months after completion of study treatment
Sabarish Ayyappan, MD
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
United States: Institutional Review Board
|MetroHealth Medical Center||Cleveland, Ohio 44109|
|Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center||Cleveland, Ohio 44106-5065|